Ipsen
Presence
Ipsen is one of the...
Ipsen is a company listed under the stock ticker IPN (FR).
Ipsen has a direct presence in 5 countries.Ipsen has 4 subsidiaries including Ipsen Iberica, Ipsen North America and Ipsen UK.
Executives
View the org chart displaying its 66 main executives
Most searched biographies at Ipsen
- David Loew, Chief Executive Officer and Director
- Anne Beaufour, Director
- Antoine Flochel, Vice Chairman of the Board of Directors
Popular executive movements at Ipsen
- Josep Catllà will join the company as Executive Vice President and Chief Corporate Affairs Officer on Aug. 19, 2024 (posted on June 7 2024).
- Stewart Campbell, Executive Vice President, President, North America, will leave the company on May 13, 2024 (posted on May 2 2024).
- Keira Driansky will join the company as Executive Vice President and President of North America on May 13, 2024 (posted on May 2 2024).
Create your alert
to follow the executive moves at Ipsen.
Pharmaceuticals
Ipsen has 1,845 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).
Popular M&A news in Pharmaceuticals
- ONO Pharmaceutical has acquired Deciphera Pharmaceuticals (posted on June 12 2024).
- AstraZeneca has acquired Fusion Pharma (posted on June 6 2024).
- Aeterna Zentaris and CeaPro have merged (posted on June 6 2024)..
Popular contacts in Pharmaceuticals
News
Press releases by Ipsen
- Ipsen appoints Keira Driansky as EVP, President of North America
- Ipsen Material Announcements
- Ipsen media releases
- https://pr.globenewswire.com/NewsArchive/View/uQHHHVjDKo-J8tcw7yWjlA==?iFrame=true
- Ipsen, today presents its sales performance for the first quarter of 2023.
- Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs - Ipsen
- Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP - Ipsen
- https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2023/03/02163748/Ipsen-completes-acquisition-of-Albireo-Press-Release-03-23.pdf
- Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
- Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
- View more press releases Close
Social media about Ipsen
- Ipsen on Wikipedia, Google News & Yahoo Finance
- Ipsen on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including David Loew 
